MARAVAI LIFESCIENCES HOLDINGS, INC.MRVIEarnings & Financial Report
Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.
Revenue
$47.4M
Gross Profit
$7.8M
Operating Profit
$-66.3M
Net Profit
$-39.6M
Gross Margin
16.4%
Operating Margin
-139.8%
Net Margin
-83.5%
YoY Growth
-31.7%
EPS
$-0.27
MARAVAI LIFESCIENCES HOLDINGS, INC. Q2 FY2025 Financial Summary
MARAVAI LIFESCIENCES HOLDINGS, INC. reported revenue of $47.4M (down 31.7% YoY) for Q2 FY2025, with a net profit of $-39.6M (down 304.4% YoY) (-83.5% margin). Cost of goods sold was $39.6M, operating expenses totaled $74.0M.
Key Financial Metrics
| Total Revenue | $47.4M |
|---|---|
| Net Profit | $-39.6M |
| Gross Margin | 16.4% |
| Operating Margin | -139.8% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
MARAVAI LIFESCIENCES HOLDINGS, INC. Q2 FY2025 revenue of $47.4M breaks down across 3 segments, led by Nucleic Acid Production Segment at $23.9M (50.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Nucleic Acid Production Segment | $23.9M | 50.4% |
| Other | $16.8M | 35.4% |
| Biologics Safety Testing Segment | $6.8M | 14.3% |
MARAVAI LIFESCIENCES HOLDINGS, INC. Revenue by Segment — Quarterly Trend
MARAVAI LIFESCIENCES HOLDINGS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Nucleic Acid Production Segment and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Nucleic Acid Production Segment | — | $17.7M | $23.9M | $22.0M |
| Other | $18.4M | $16.6M | $16.8M | $17.6M |
| Biologics Safety Testing Segment | — | $7.3M | $6.8M | $7.3M |
MARAVAI LIFESCIENCES HOLDINGS, INC. Annual Revenue by Year
MARAVAI LIFESCIENCES HOLDINGS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $185.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $185.7M |
| 2024 | $259.2M |
| 2023 | $288.9M |
| 2022 | $883.0M |
MARAVAI LIFESCIENCES HOLDINGS, INC. Quarterly Revenue & Net Profit History
MARAVAI LIFESCIENCES HOLDINGS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $49.9M | -11.8% | $-35.7M | -71.6% |
| Q3 FY2025 | $41.6M | -39.7% | $-25.6M | -61.4% |
| Q2 FY2025 | $47.4M | -31.7% | $-39.6M | -83.5% |
| Q1 FY2025 | $46.9M | -27.0% | $-29.9M | -63.9% |
| Q4 FY2024 | $56.6M | -23.7% | $-25.9M | -45.8% |
| Q3 FY2024 | $69.0M | +3.2% | $-97.1M | -140.6% |
| Q2 FY2024 | $69.4M | +0.7% | $-9.8M | -14.1% |
| Q1 FY2024 | $64.2M | -18.8% | $-12.1M | -18.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $64.2M | $69.4M | $69.0M | $56.6M | $46.9M | $47.4M | $41.6M | $49.9M |
| YoY Growth | -18.8% | 0.7% | 3.2% | -23.7% | -27.0% | -31.7% | -39.7% | -11.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.44B | $1.44B | $1.28B | $1.01B | $959.8M | $897.0M | $849.2M | $770.6M |
| Liabilities | $667.3M | $671.3M | $665.6M | $431.0M | $429.5M | $429.0M | $417.3M | $397.9M |
| Equity | $410.7M | $434.7M | $344.9M | $325.3M | $300.6M | $265.9M | $245.4M | $212.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.5M | $17.4M | $13.1M | $-14.6M | $-9.4M | $-10.3M | $-15.2M | $-22.8M |